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The economic costs of knee osteoarthritis (OA)
and its treatment are important considerations
for patients, physicians, and healthcare systems
when making decisions about the management
of knee OA, especially given the direct costs
associated with total knee replacement (TKR)
[1, 2], and the estimated increase in demand by
2030 projected for TKR in the United States
(673% increase from 2005 for primary TKR) [3].
Viscosupplementation has been shown to delay
the time to TKR [4–6], making it an attractive
option for delaying or reducing healthcare costs
due to TKR. However, users of the treatment
have a number of Food and Drug
Administration (FDA)-approved
viscosupplementation products with
potentially different cost-benefit impacts from
which to choose. These include, among others,
Euflexxa (Ferring Pharmaceuticals Inc.,
Parsippany, NJ, USA), GelSyn-3TM/SupartzTM
(Bioventus, Durham, NC, USA), Hyalgan
(Fidia Pharma Inc., Parsippany, NJ, USA),
Orthovisc (DePuy Synthes, Warsaw, IN, USA),
and Synvisc/Synvisc-One (Sanofi,
Bridgewater, NJ, USA). The purpose of the
study by Rosen et al. [7] was to indirectly
evaluate the cost-effectiveness of different
forms of intra-articular (IA) hyaluronic acid
(HA) injections for the treatment of knee OA
based on efficacy data that were extracted from
a select set of randomized controlled trials and
converted into utility scores. We have serious
concerns regarding this approach, especially
with some of the assumptions made by Rosen
et al. [7] and in light of other available data not
included in their analysis. Our concerns are
outlined below.
First, the study selection approach the
authors employed did not result in adequate
representation of available
viscosupplementation treatments. They
conducted a systematic search for randomized
controlled trials that each examined the use of
IA-HA in knee OA and reported full Western
Ontario and McMaster Universities Index
(WOMAC) pain, stiffness, and functional
outcome data in a 5-point Likert format at
both baseline and 6-month follow-up. Their
search yielded just five articles with information
on only five products [one article each for
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Durolane (Bioventus, Durham, NC, USA),
Euflexxa, Hyalgan, and Synvisc, and two for
Supartz (one shared with Synvisc)]. This is a
small, nonrepresentative sample for a
cost-effectiveness analysis. In addition, this
selection process excluded often-used products
such as Synvisc-One, which had an average
patient market share of 24.7% for the period of
June 2015–May 2016 [8], thereby rendering the
analysis incomplete. Ensuring that all available
products are included in this type of study is
particularly important when analyzing this
market. Specifically, IA-HA products have
different dosing-for-efficacy regimens (e.g., one
injection vs three weekly injections for
6 months of symptom relief), which has a
direct impact on cost—assuming comparable
efficacy, six injections per year (three
injections/6 months) is obviously three times
the number of injections as two (one injection/
6 months).
The importance of this omission can be
demonstrated directly by comparing the
calculated cost of Synvisc-One (one injection
for 6 months of efficacy [9]) with that of
Euflexxa (three injections for 6 months of
efficacy [10]) in a specific population of
commercial health plan covered lives (e.g.,
Blue Cross Blue Shield HighMark: 5.2 million
[11]) using a single payer perspective similar to
the approach taken by Rosen et al. [7].
Synvisc-One may also be more appropriate
than Durolane to include in this analysis
because, unlike Durolane, Synvisc-One is
FDA-approved. Our model focuses on OA
patients C60 years of age and assumes a
conservative estimate (based on previous
reports [4, 12]) that 20% of these patients will
receive IA-HA treatment. Given that 18.5% of
the US population is C60 years of age [13] and
that the prevalence of knee OA is 37.4% among
adults [14], this model yields 71,917 prospective
patients. When our model is used to compare
Synvisc-One and Euflexxa, it demonstrates that
if the approximately 72,000 Americans who use
viscosupplements to treat their knee OA in the
model were to switch from Euflexxa to
Synvisc-One, the savings benefit in switching
from Euflexxa’s annual cost of $4001.64 to
Synvisc-One’s annual cost of $3086.66 [annual
out-of-pocket (defined as cost of
treatment ? cost of treatment administration)]
would result in each patient saving $914.98 per
year.
Our model includes the direct costs of the
product itself and the cost of administration.
However, patients may experience additional
burden associated with direct as well as
indirect costs attributable to an increased
number of office visits for those additional
injections. Patients would likely have to pay
additional co-payments for those visits.
Moreover, patients may experience higher
indirect costs such as loss of salary due to
utilization of work time for injection visits,
the need to use employer-provided time off,
and cost of travel to the physician. Our
concerns with the Rosen et al. article [7] do
not pertain solely to the exclusion of
Synvisc-One from the analysis. It could be
argued that it is not surprising the cost of a
medication administered only twice a year is
lower than that of a medication administered
six times a year. However, when Euflexxa is
compared with a 3-injection regimen of either
Hyalgan or Supartz (as was used in Rosen et al.
[7]) using our model, patients who switch
from Euflexxa to Supartz would realize an
annual savings of $592.56 and patients who
switch to Hyalgan would save $709.92 per
year.
Second, we have concerns regarding the
methodology used to extract data from the
selected studies. Because cost-effectiveness
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evaluation is a comparison of incremental
efficacy gained given cost, the efficacy data
selected must be comparable. In the Rosen et al.
analysis [7], however, the data from one of the
five articles that met the selection criteria set
forth by the authors, the Altman et al. article
[15], was not used directly in their analysis.
Rather, utility scores for Euflexxa were
secondarily abstracted from a different article,
Hatoum et al. [16], which is a cost-effectiveness
analysis of the data in the Altman et al. article
[15]. The data in Altman et al. [15] that were
analyzed in Hatoum et al. [16] were also
reported on a 100-mm visual analog scale
rather than on the 5-point Likert scale format
set forth as a requirement for the study
selection, and were from both a randomized
controlled study (as per the selection approach)
and an open-label extension study that
followed it. Given the different approaches
used to convert efficacy data into utility data,
it is difficult to interpret the baseline utility
scores for the different products presented in
Rosen et al. [7], which differ substantially. In
addition to differences in data conversion
contributing to differences in utility scores,
variability may also result from efficacy
differences among products in similar patient
populations and/or similar efficacy but in
varying patient populations. It is very difficult
to reliably interpret the scores given in the
article without information on factors that may
contribute to variability in the analysis.
In conclusion, measuring cost-effectiveness
depends on both cost and efficacy measures,
which in the end depend on the integrity of
the data used, how representative they are, and
the model applied. A more direct, and
therefore, more accurate approach, which has
been used for other diseases ranging from pain
and generalized anxiety disorders [17] to
fibromyalgia [18], would be to assess
health-related quality-of-life and utility
measures directly as outcome measures in
clinical trials. This would clarify the data
collection and extraction processes, making
comparisons easier to interpret within a
real-world context for all users of the
treatment. In considering cost-effectiveness of
IA-HA treatments for OA, specifically, the issue
becomes complicated by the delivery method
needed for viscosupplementation. An increase
in the number of injections is associated not
only with the cost of the treatment and the
cost of administration but also with additional
direct costs (e.g., additional co-payments) and
with indirect costs such as requiring time off
from work. Therefore, these considerations
must be included in a comprehensive
evaluation of the cost-effectiveness of these
products. Although Rosen et al. [7]
acknowledge that this cost analysis represents
‘‘a single payer, base-case scenario,’’ they do
not fully acknowledge the complexity of this
disorder and its treatment. For these reasons,
we believe the overly confident conclusions
drawn by the authors must be interpreted with
caution, and we look forward to other
investigative efforts to assist patients,
physicians, and healthcare systems in
choosing the best care for their patients with
OA of the knee.
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